Ciba-Geigy/Gipharmex Deursil
Executive Summary
Gallstone dissolver, approved Dec. 31, will be marketed in U.S. by Ciba-Geigy under licensing agreement with ltalian firm Gipharmex S.p.A. Ciba-Geigy said it assumes on Jan. 9 all rights to Deursil's approved NDA. Ciba-Geigy plans to launch Deursil 150 mg and 300 mg caps in the latter part of 1988. Deursil is indicated for "patients with radiolucent,-non-calcified, gallbladder stones" who carry high surgical risk or who refuse surgery.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.